First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination

Konstantinos Savvatis 1
Dirk Westermann 1
Heinz-Peter Schultheiss 1
Carsten Tschöpe 1,2

1 Charité Universitätsmedizin Berlin, Department of Cardiology and Pneumonology, Campus Benjamin Franklin, Berlin; 2 Charité Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Campus Virchow-Klinikum, Berlin, Germany

Abstract: Arterial hypertension is one of the major diseases in the Western world. It is an independent cardiovascular risk factor and is associated with increased morbidity and mortality. Several drug classes have been shown to be effective in the treatment of hypertension. Aliskiren is a direct renin inhibitor and belongs to the class of renin-angiotensin-aldosterone system inhibitors. Several large studies have shown that aliskiren is effective in lowering blood pressure, and equivalent in this respect to the angiotensin-converting enzyme (ACE) inhibitors and the angiotensin receptor-1 blockers (ARBs). Furthermore, aliskiren has a safety and tolerability profile comparable with that of the ARBs and slightly better than that of the ACE inhibitors. From a pathophysiologic perspective, it can be combined with hydrochlorothiazide successfully, because it can block the diuretic-induced increase in plasma renin activity. Its combination with hydrochlorothiazide in a single pill has been investigated and shown to be superior to monotherapy with respect to blood pressure control and improvement in patient compliance with therapy. Further studies are needed to show whether aliskiren and its combination with hydrochlorothiazide is effective in preventing cardiovascular events and mortality when end organ damage is present.

Keywords: aliskiren, hydrochlorothiazide, combination, hypertension

Introduction

Arterial hypertension is one of the most common diseases in the developed world. It is one of the major cardiovascular risk factors for development of coronary heart disease, heart failure, stroke, and chronic kidney disease. In 2000, more than 970 million people worldwide had elevated blood pressure, and this number is expected to have increased by 60% in 2025.1 According to the World Health Organization, arterial hypertension accounts for 7.1 million deaths per year, and this number is expected to rise in the future.2

The guidelines of the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7), as well as those of the European Society of Cardiology and European Society of Hypertension recommend a target blood pressure lower than 140/90 mmHg in uncomplicated hypertension and lower than 130/80 mmHg when additional risk factors, such as diabetes or coronary heart disease, are present.3,4 Despite these recommendations and the existence of many different antihypertensive drugs, hypertension in the US is only controlled in about 30%–60% of patients, and this rate is much lower in western European countries.5,6 At least 75% of hypertensive patients require combination therapy to achieve current blood pressure goals.7–9 Combination of several agents allows for synergistic action
and use of lower doses of the individual drugs, leading to a reduction in side effects and improvement of patient compliance.\textsuperscript{10} Therefore, combination treatment as first-line therapy is a logical choice for patients with moderate to severe hypertension.

The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in the pathophysiology of hypertension and cardiovascular diseases.\textsuperscript{11} Drugs that target the RAAS, such as angiotensin-converting enzyme (ACE) inhibitors and blockers of angiotensin receptor-1 (ARBs), are effective in reducing blood pressure, as well as the morbidity and mortality associated with hypertension and cardiovascular diseases. Their low rate of side effects makes them well tolerated and therefore attractive as first-line agents in the treatment of arterial hypertension.\textsuperscript{12} Blockers of the RAAS are widely combined with thiazide diuretics, mainly hydrochlorothiazide, a strategy supported pathophysiologicaly by the mechanism of action of the two drug classes. Hydrochlorothiazide leads to activation of the RAAS through sodium and water depletion, which limits its antihypertensive effects (Table 1), and its combination with a RAAS blocker potentiates the effects of both agents.\textsuperscript{13}

A recent addition to the family of RAAS-blockers is aliskiren, a direct renin inhibitor, now approved for the treatment of hypertension. Several studies have already investigated the effects of aliskiren as monotherapy in lowering blood pressure and in combination with other agents, including calcium channel blockers and hydrochlorothiazide. At present, aliskiren is available as a fixed combination with hydrochlorothiazide in several dose strengths, ie, 150/12.5 mg, 150/25 mg, 300/12.5 mg, and 300/25 mg, and is approved as second-line treatment in patients whose blood pressure is not adequately controlled by the individual drugs alone. This review focuses on the efficacy of the combination of aliskiren with hydrochlorothiazide as a potential first-line treatment of hypertension.

### Renin-angiotensin-aldosterone inhibitors

The RAAS is a system of active peptides and enzymes, mainly responsible for fluid and electrolyte homeostasis and vascular tone (see Figure 1). Furthermore, RAAS plays an important role in inflammation, cellular and organ hypertrophy, and fibrosis, and activation of this system is therefore important in the pathophysiology of cardiovascular diseases, including hypertension, myocardial infarction, heart and kidney failure, and stroke.\textsuperscript{14,15}

The RAAS cascade begins with renin, an aspartyl protease released by the juxtaglomerular cells of the kidney into the circulation, which consists of two homologous lobes with a cleft in between containing two catalytic aspartic residues.\textsuperscript{16} Renin is produced by proteolytic transformation of its proenzyme, prorenin.\textsuperscript{17} Renin acts on angiotensinogen and converts it to angiotensin I. This is the rate-limiting step of RAAS activation. Angiotensin I is converted to angiotensin II in the lungs through the action of ACE. Traditionally, angiotensin II is considered to be the major effector molecule of the RAAS. Angiotensin II exerts its effects mainly through its Type 1 (AT\textsubscript{1}) receptors in target organs, but several other types of receptors exist, the actions of which are as yet not entirely clear.\textsuperscript{18} Angiotensin II also acts on the adrenal cortex, leading to the release of aldosterone into the circulation.

Blockade of the RAAS using ACE inhibitors and AT\textsubscript{1} receptor blockers has been the mainstay of medical treatment for cardiovascular disease for the last two to three decades. ACE inhibitors inhibit the action of ACE and disrupt the conversion of angiotensin I into angiotensin II. ARBs act on AT\textsubscript{1} receptors and directly block the actions of angiotensin II on target organs. RAAS inhibition using ACE inhibitors or ARBs has been proven to be effective in reducing elevated blood pressure, preventing and slowing the progression of cardiovascular disease, and reducing the associated morbidity and mortality.\textsuperscript{19}

### Table 1: Effects of RAAS blockers and common antihypertensive agents on different RAAS components

<table>
<thead>
<tr>
<th>Agent</th>
<th>PRC</th>
<th>PRA</th>
<th>Angiotensinogen</th>
<th>Angiotensin I</th>
<th>Angiotensin II</th>
<th>Angiotensin I–7</th>
<th>Aldosterone</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-blockers</td>
<td>↓</td>
<td>↓</td>
<td>–</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Calcium antagonists</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Diuretics</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>ACEi</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>ARBs</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>Aliskiren</td>
<td>↑↑</td>
<td>↓</td>
<td>–</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Aliskiren-HCTZ</td>
<td>↑↑↑</td>
<td>↓</td>
<td>–</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; HCTZ, hydrochlorothiazide; PRC, plasma renin concentration; PRA, plasma renin activity; RAAS, renin-angiotensin-aldosterone system.
Aliskiren-hydrochlorothiazide: Pharmacokinetics and pharmacodynamics

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

However, after some months of treatment with ACE inhibitors, levels of angiotensin II in the blood start to rise again, which is known as the “angiotensin escape phenomenon”. Furthermore, both ACE inhibitors and ARBs lead to a compensatory increase in plasma renin concentration and plasma renin activity. An increase in plasma renin activity may ultimately lead to increased angiotensin II production, which, in turn, may act on receptors other than the AT1 receptor, with potentially harmful effects. However, the exact clinical importance of this phenomenon remains unknown.

Aliskiren is the newest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

However, after some months of treatment with ACE inhibitors, levels of angiotensin II in the blood start to rise again, which is known as the “angiotensin escape phenomenon”.20 Furthermore, both ACE inhibitors and ARBs lead to a compensatory increase in plasma renin concentration and plasma renin activity. An increase in plasma renin activity may ultimately lead to increased angiotensin II production, which, in turn, may act on receptors other than the AT1 receptor, with potentially harmful effects. However, the exact clinical importance of this phenomenon remains unknown.

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step.21 Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

However, after some months of treatment with ACE inhibitors, levels of angiotensin II in the blood start to rise again, which is known as the “angiotensin escape phenomenon”.20 Furthermore, both ACE inhibitors and ARBs lead to a compensatory increase in plasma renin concentration and plasma renin activity. An increase in plasma renin activity may ultimately lead to increased angiotensin II production, which, in turn, may act on receptors other than the AT1 receptor, with potentially harmful effects. However, the exact clinical importance of this phenomenon remains unknown.

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.

Aliskiren is the latest member of the RAAS blocker class of drugs. It acts directly on renin and inhibits its action, thereby blocking the activation of RAAS and the production of angiotensin II directly at its rate-limiting step. Aliskiren binds the active site of renin and inhibits its catalytic activity. The action of aliskiren at this early upstream step has the potential to block the action of angiotensin more effectively than the other known RAAS blockers.
concentration and plasma renin activity is further potentiated when hydrochlorothiazide is combined with an ACE inhibitor or ARB. However, aliskiren was able to suppress plasma renin activity when combined with hydrochlorothiazide 25 mg/day in a study of hypertensive obese patients.32 Interestingly, aliskiren also decreases plasma renin activity when combined with other agents known to increase plasma renin activity, including ACE inhibitors and ARBs.27

**Use of aliskiren-hydrochlorothiazide in hypertension**

Successful use of aliskiren as monotherapy in hypertension has been demonstrated in several studies, and has been extensively reviewed elsewhere.33-35 Doses of 150–300 mg once daily have been shown to have similar antihypertensive effects as comparable doses of ACE inhibitors and ARBs.35 Interestingly, the antihypertensive effects of aliskiren lasted surprisingly longer than its half-life in blood and persisted for a month after discontinuation of the drug in a study by Andersen et al.29 This observation is confirmed by a meta-analysis of eight studies showing that stopping treatment with aliskiren does not lead to a paradoxical increase in blood pressure.36

In a placebo-controlled study of 455 Japanese patients with hypertension and a mean sitting diastolic blood pressure of 95–110 mmHg, aliskiren in doses of 75, 150, and 300 mg lowered blood pressure in a dose-dependent manner. Interestingly, after correcting for placebo, the reduction in systolic and diastolic blood pressure was 5.7/4 mmHg, 5.9/4.5 mmHg, and 11.2/7.5 mmHg, respectively, indicating a rather small effect.37

Several other studies have compared different doses of aliskiren with the ARBs, irbesartan, losartan, and valsartan, as well as valsartan-hydrochlorothiazide and valsartan-aliskiren combinations.38-40 In all studies, aliskiren was effective in the lowering of blood pressure compared with placebo and to a similar extent with comparable doses of the ARBs tested. Furthermore, the combination of valsartan-aliskiren had a stronger antihypertensive effect than monotherapy, and was as effective as the valsartan-hydrochlorothiazide combination. These findings were confirmed in a meta-analysis showing that aliskiren is as effective for blood pressure reduction as the ACE inhibitors and ARBs.35

Hydrochlorothiazide is the most commonly prescribed antihypertensive drug in the US, and remains the drug of choice for uncomplicated hypertension in the JNC 7 recommendations. However, the most commonly prescribed doses of hydrochlorothiazide are 12.5 and 25 mg. Surprisingly, all the major studies were performed using higher hydrochlorothiazide doses or hydrochlorothiazide in combination with other antihypertensive agents, so little or no evidence exists for the efficacy of low-dose hydrochlorothiazide in hypertension and cardiovascular disease. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), one of the major studies showing equivalent efficacy of diuretics and other antihypertensives, was performed with chlorthalidone, which seems to be more effective than hydrochlorothiazide.41,42 Furthermore, hydrochlorothiazide at higher doses whereby its efficacy might be comparable with that of other antihypertensives, shows many adverse effects, including electrolyte imbalance (hypokalemia, hyponatremia), insulin resistance, and hyperuricemia, making it inappropriate as monotherapy.43 However, low-dose hydrochlorothiazide remains effective in lowering blood pressure, and from a pathophysiologic perspective, combines well with the RAAS inhibitors, including aliskiren.

Several trials have investigated the use of aliskiren and hydrochlorothiazide alone and in combination for treatment of hypertension (Table 2). In the largest trial to date, Villamil et al investigated the effects of aliskiren and hydrochlorothiazide in 2776 patients with mild hypertension and mean sitting diastolic blood pressure 95–109 mmHg. Aliskiren was used as monotherapy in doses of 75, 150, and 300 mg once daily, hydrochlorothiazide in doses of 6.25, 12.5, and 25 mg, and their combination included all possible doses except for the aliskiren-hydrochlorothiazide combination of 300/6.25 mg. The study was of double-blind, randomized, placebo-controlled design and of eight weeks’ duration. Both drugs reduced blood pressure significantly compared with placebo, and interestingly, to the same extent for comparable doses of aliskiren and hydrochlorothiazide. Combination of the drugs lowered both diastolic and systolic blood pressure to a greater extent than either drug used alone. The response rates were also higher with the aliskiren-hydrochlorothiazide combination. Increased plasma renin activity and hypokalemia rates seen with hydrochlorothiazide monotherapy were reversed by addition of aliskiren, while the risk of hypokalemia in the combination groups was only slightly higher than with placebo.44 Post hoc analysis of the data showed that most of the dose combinations of aliskiren-hydrochlorothiazide were also superior to monotherapy in individuals with Stage 2 hypertension (mean sitting systolic blood pressure >160 mmHg).44

In a study of 489 obese hypertensive patients already treated with hydrochlorothiazide 25 mg, Jordan et al examined the antihypertensive effects of the addition of aliskiren 300 mg, irbesartan 300 mg, or amlopidine 10 mg. The patients were unresponsive to previous monotherapy
with hydrochlorothiazide. Addition of aliskiren led to a significant reduction of blood pressure compared with a placebo-hydrochlorothiazide combination after eight weeks of treatment. Interestingly, the regimens including irbesartan 300 mg and amlopidine 10 mg had similar antihypertensive effects to those of the aliskiren-hydrochlorothiazide combination. However, the amlopidine-hydrochlorothiazide combination was less well tolerated as a result of an increased rate of peripheral edema. Plasma renin activity was, as expected, lower in the regimens tolerated as a result of an increased rate of peripheral edema.

### Safety and tolerability

It is important for a drug to be safe and well tolerated by patients. Overall, aliskiren in combination with hydrochlorothiazide was shown to be safe in various studies. Adverse effects were mild, and commonly included

### Table 2 Important studies comparing the effects of the aliskiren/hydrochlorothiazide combination with other treatment regimens

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients (n)</th>
<th>Regimen</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Villamil</td>
<td>2776</td>
<td>Ali 75-150-300, HCTZ 6.25-12.5-25, Ali-HCTZ all comb. except 300/6.25</td>
<td>Comparable doses of Ali and HCTZ equally effective in lowering BP, comb; achieved further BP reduction</td>
</tr>
<tr>
<td>Jordan</td>
<td>489</td>
<td>Ali-HCTZ 300/25, Irb-HCTZ 300/25, Aml-HCTZ 10/25, HCTZ 25</td>
<td>All combinations equally effective in lowering BP and better than HCTZ alone; Aml-HCTZ less tolerable due to edema, hypokalemia</td>
</tr>
<tr>
<td>Duprez</td>
<td>901</td>
<td>Ali 150 → 300, Ramipril 5 → 10, Add-on HCTZ 25 after 12 weeks and Aml 10 mg after 22 weeks, if needed</td>
<td>All group achieved target BP with the addition of fewer drugs</td>
</tr>
<tr>
<td>Strasser</td>
<td>183</td>
<td>Ali 150 → 300, Lis 20 → 40, Add-on HCTZ 25 as needed</td>
<td>Ali and Lis equally effective in lowering BP, HCTZ addon in similar number of pts in both groups needed</td>
</tr>
<tr>
<td>Nickenig</td>
<td>880</td>
<td>Single-pill Ali-HCTZ 300/12.5 or 300/25 versus Ali 300 alone</td>
<td>Single-pill comb more effective in BP lowering than monotherapy, similarly well tolerated</td>
</tr>
<tr>
<td>Blumenstein</td>
<td>722</td>
<td>Single-pill Ali-HCTZ 150/25 or 300/25 versus HCTZ 25 alone</td>
<td>Single-pill more efficient in lowering BP than monotherapy, similarly well tolerated, less hypokalemia with the single-pill combination</td>
</tr>
</tbody>
</table>

Note: Arrows indicate uptitration of the drug from the initial to the final dose.

**Abbreviations:** Ali, aliskiren; Aml, amlopidine; BP, blood pressure; HCTZ, hydrochlorothiazide; Irb, irbesartan; Lis, lisinopril; pts, patients.
headache (6% versus 9% with placebo), dizziness (2.5% versus 1% with placebo), diarrhea (1.8% versus 0.5% with placebo), and flu-like symptoms (2.5% versus 1.6% with placebo).31,32,40,46,48 Hypokalemia was significantly lower for the aliskiren-hydrochlorothiazide combination (1%–2% in the combinations with hydrochlorothiazide 12.5 mg and 2%–3% in those with hydrochlorothiazide 25 mg) compared with hydrochlorothiazide alone (4%–5%) and slightly higher than in the placebo groups (1%) and for the irbesartan-hydrochlorothiazide combination, especially in obese patients.31,32 Cough (1.5% versus 0.5% with placebo) presents less often than with ACE inhibitors and at a similar rate to that with ARBs. Hyperkalemia might be of concern, especially when aliskiren is used in conjunction with an ACE inhibitor or an ARB.

Cost comparison with other first-line treatments
An important aspect of antihypertensive drugs is their cost-effectiveness. Aliskiren both alone and in combination with hydrochlorothiazide is able to reduce blood pressure to a similar degree as ACE inhibitors and ARBs (and their combinations with hydrochlorothiazide). Treatment costs vary widely from country to country. However, the cost of aliskiren is similar to that of ARBs and much higher than that of the older ACE inhibitors. With ARBs and aliskiren being as effective in lowering blood pressure as the ACE inhibitors and slightly better tolerated than the latter, treatment with an ACE inhibitor seems to be the logical first choice, with ARBs and aliskiren reserved for selected patients who cannot tolerate ACE inhibitors. Interestingly, aliskiren seems also to be as effective as hydrochlorothiazide and amlodipine, which are much cheaper treatment options. However, the tolerability of hydrochlorothiazide and amlodipine is inferior to that of aliskiren and they tend to have more side effects, including electrolyte disorders and edema.

Effects of aliskiren on cardiovascular disease outcomes
Of great importance is the effect of aliskiren on outcomes in patients with cardiovascular disease and end organ damage. Several preclinical studies have demonstrated favorable effects of aliskiren on cardiac hypertrophy, myocardial function and remodeling after myocardial infarction, and kidney failure.49,50 However, there are no data available as yet showing a benefit of aliskiren in reducing cardiovascular mortality. Most studies have investigated the effects of aliskiren on biomarkers or surrogate outcomes, while large prospective trials with mortality outcomes are expected to be completed in the near future.

The ALiskiren Observation of Heart Failure Study (ALOFT) investigated the effects of add-on treatment with aliskiren 150 mg in 302 patients with stable heart failure (New York Heart Association II–IV) and hypertension, previously on ACE inhibitors or ARBs and beta-blockers.51 Addon aliskiren therapy significantly reduced the levels of N-terminal pro brain natriuretic peptide, without additional risk of hyperkalemia, hypotension, or worsening renal function. In the Aliskiren in Left Ventricular Hypertrophy (ALLAY) study, treatment with aliskiren 300 mg was noninferior to losartan 100 mg in reducing left ventricular hypertrophy.52 However, in the recently presented ASPIRE (Aliskiren Study in Post-MI Patients to Reduce Remodeling) trial, aliskiren titrated to 300 mg on top of an ACE inhibitor or an ARB failed to show any improvement in myocardial remodeling after acute myocardial infarction and left ventricular ejection fraction below 45%, while an increase in adverse effects was observed.53 In the AVOID trial (Aliskiren in the eValuation of prOteinuria in Diabetes), 599 hypertensive diabetics with diabetic nephropathy and proteinuria were treated with aliskiren 300 mg or placebo on top of previous treatment with 100 mg losartan.54 Aliskiren reduced the albumin-creatinine ratio by 20% compared with placebo after six months of treatment.

The findings of two large-scale trials, ie, ALTITUDE (Aliskiren Trial In Type 2 Diabetes Using Cardio-Renal Disease Endpoints) and ATMOSPHERE (Aliskiren Trial to Minimize OutcomeS in Patients with Heart FailuRE) are awaited with great interest. The aim of ALTITUDE is to examine whether aliskiren is able to reduce cardiovascular and renal morbidity and mortality when used on top of pre-existing therapy with an ACE inhibitor or an ARB in high-risk patients with Type 2 diabetes. ATMOSPHERE is investigating the effects of aliskiren on cardiovascular death and rehospitalization in patients with chronic heart failure.

Lessons from the ACCOMPLISH trial
ACE inhibitors and ARBs have been shown to reduce cardiovascular morbidity and mortality in many different patient groups and are considered first-line drugs in such patients. It is therefore intriguing to suggest, in expectation of large outcome trials, that aliskiren is also going to show similar results. However, cardiovascular patients tend to need more than one drug to control their hypertension. Therefore, it would be interesting to find an effective partner drug for
the RAAS inhibitors. Hydrochlorothiazide has been the standard add-on drug when monotherapy is inadequate. The recent ACCOMPLISH trial (Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension) has shown that the combination of benazepril (an ACE inhibitor) and amlodipine prevents cardiovascular events more effectively than the combination of benazepril and hydrochlorothiazide. Therefore, one could speculate that amlodipine might be a more appropriate partner for aliskiren than hydrochlorothiazide in patients with hypertension and no signs of volume overload, where a diuretic would be more appropriate.

**Conclusion**

Only 30% of hypertensive patients reach target blood pressure with monotherapy, and 70% require one or more additional agents. Fixed-drug combinations can improve patient compliance, and their use is supported by current guidelines for treatment of arterial hypertension. The combination of a RAAS inhibitor with hydrochlorothiazide is effective and reasonable because it potentiates the antihypertensive effects and lowers side effects of the component drugs. Aliskiren and its combination with hydrochlorothiazide appear to be as effective as ARBs and ACE inhibitors in the treatment of uncomplicated hypertension and as safe and tolerable as the ARBs and slightly better than the ACE inhibitors. However, there are still no clinical studies showing a mortality benefit for aliskiren or reduction of end organ damage, as are available for the ACE inhibitors and ARBs. Furthermore, the effects of reduced plasma renin activity and increased plasma renin concentration induced by aliskiren remain to be shown in large prospective studies and, while there are interesting experimental data, their clinical importance remains unclear.

Finally, it is intriguing to consider the findings of the recent ACCOMPLISH study and speculate that the combination of aliskiren with a calcium antagonist might be an even better combination, especially for patients with metabolic disorders and high cardiovascular risk.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


